Conditional estimation and inference to address observed covariate imbalance in randomized clinical trials

2018 ◽  
Vol 16 (2) ◽  
pp. 122-131 ◽  
Author(s):  
Zhiwei Zhang ◽  
Linli Tang ◽  
Chunling Liu ◽  
Vance W Berger

Background Baseline covariate imbalance (between treatment groups) is a common problem in randomized clinical trials which often raises questions about the validity of trial results. Answering these questions requires careful consideration of the statistical implications of covariate imbalance. The possibil ity of having covariate imbalance contributes to the marginal variance of an unadjusted treatment difference estimator, which can be reduced by making appropriate adjustments. Actual observed imbalance introduces a conditional bias into an unadjusted estimator, which may increase the conditional size of an unadjusted test. Methods This article provides conditional estimation and inference procedures to address the conditional bias due to observed imbalance. Interestingly, it is possible to use the same adjusted treatment difference estimator to address the marginal variance issue and the conditional bias issue associated with covariate imbalance. Its marginal variance estimator tends to be conservative for conditional inference, and we propose a conditionally appropriate variance estimator. We also provide an estimator of the conditional bias in an unadjusted treatment difference estimator, together with a conditional variance estimator. Results The proposed methodology is illustrated with real data from a stroke trial and evaluated in simulation experiments based on the same trial. The simulation results show that covariate imbalance can result in a substantial conditional bias and that the proposed methods deal with the conditional bias quite effectively. Discussion We recommend that the proposed methodology be used routinely to address the observed covariate imbalance in randomized clinical trials.

Author(s):  
Bente Lomholt Langdahl ◽  
Lorenz Christian Hofbauer ◽  
John Colin Forfar

Abstract Sclerostin is primarily produced by the osteocytes, inhibits the canonical Wnt pathway and thereby the osteoblasts, and stimulates RANKL release by the osteocytes and thereby osteoclast recruitment. Inhibition of sclerostin therefore causes stimulation of bone formation and inhibition of resorption. In clinical trials romosozumab, an antibody against sclerostin, increases BMD and reduces the risk of fractures compared to placebo and alendronate. The cardiovascular safety of romosozumab was adjudicated in 2 large clinical osteoporosis trials in postmenopausal women. Compared with placebo, the incidence of cardiovascular events was similar in the two treatment groups. Compared to alendronate, the incidence of serious cardiovascular events was higher in women treated with romosozumab. The incidence of serious cardiovascular adverse events was low and posthoc analyses should therefore be interpreted with caution, however, the relative risk seemed unaffected by preexisting cardiovascular disease or risk factors. Sclerostin is expressed in the vasculature, predominantly in vascular smooth muscle cells in the media. However, preclinical and genetic studies have not demonstrated any increased cardiovascular risk with continuously low sclerostin levels or inhibition of sclerostin. Furthermore, no potential mechanisms for such an effect have been identified. In conclusion, while there is no preclinical or genetic evidence of a harmful effect of sclerostin inhibition on cardiovascular safety, the evidence from the large clinical trials in postmenopausal women is conflicting. Romosozumab should therefore be used for the treatment of postmenopausal women with osteoporosis at high risk of fracture after careful consideration of the cardiovascular risk and the balance between benefits and risks.


2014 ◽  
Vol 26 (2) ◽  
pp. 776-795
Author(s):  
Zhiwei Zhang ◽  
Kyeongmi Cheon

A common problem in randomized clinical trials is nonignorable missingness, namely that the clinical outcome(s) of interest can be missing in a way that is not fully explained by the observed quantities. This happens when the continued participation of patients depends on the current outcome after adjusting for the observed history. Standard methods for handling nonignorable missingness typically require specification of the response mechanism, which can be difficult in practice. This article proposes a reverse regression approach that does not require a model for the response mechanism. Instead, the proposed approach relies on the assumption that missingness is independent of treatment assignment upon conditioning on the relevant outcome(s). This conditional independence assumption is motivated by the observation that, when patients are effectively masked to the assigned treatment, their decision to either stay in the trial or drop out cannot depend on the assigned treatment directly. Under this assumption, one can estimate parameters in the reverse regression model, test for the presence of a treatment effect, and in some cases estimate the outcome distributions. The methodology can be extended to longitudinal outcomes under natural conditions. The proposed approach is illustrated with real data from a cardiovascular study.


Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.


2001 ◽  
Vol 21 (02) ◽  
pp. 77-81 ◽  
Author(s):  
G. Finazzi

SummaryThrombotic events are a major clinical problem for patients with antiphospholipid antibodies (APA). However, current recommendations for their prevention and treatment are still based on retrospective studies. Data from large scale, prospective clinical trials are required to ultimately identify the optimal management of these patients. To date, at least four randomized studies are underway. The WAPS and PAPRE clinical trials are aimed to establish the correct duration and intensity of oral anticoagulation in APA patients with major arterial or venous thrombosis. The WARSS-APASS is a collaborative study to evaluate the efficacy and safety of aspirin or low-dose oral anticoagulants in preventing the recurrence of ischemic stroke. The recently announced UK Trial compares low-dose aspirin with or without low-intensity anticoagulation for the primary prevention of vascular events in APA-positive patients with SLE or adverse pregnancy history, but still thrombosis-free. It is hoped that the results of these trials will be available soon since clinicians urgently need more powerful data to treat their patients with the APA syndrome.


Author(s):  
Glêbia A. Cardoso ◽  
Mateus D. Ribeiro ◽  
Ana P. Ferreira ◽  
Yohanna de Oliveira ◽  
Thiago de O. Medeiros ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document